---
document_datetime: 2026-02-16 09:43:02
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ibuprofen-genorph-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ibuprofen-genorph-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4554469
conversion_datetime: 2026-02-18 17:50:24.524631
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Ibuprofen Gen.Orph

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IB /  | C.2 Change(s) in the summary of product | 13/02/2026                          |                                             | SmPC and PL                      | To update Sections 4.4 and 4.8 of the SmPC and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000325757                     | characteristics, labelling or package leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.2.a) Implementation of change(s) for which no new additional data is required to be submitted by the holder - Accepted C.2.a (Type IB) - To update Sections 4.4 and 4.8 of the SmPC and Sections 2 and 4 of the PL to include information on the side effect Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome), following approval of the same change for the reference product Pedea. Additionally, the MAH introduced editorial updates: (1) aligning Section 4.9 of the SmPC and Section 3 of the PL with the reference product, and (2) correcting a typographical error in Table   |            | Sections 2 and 4 of the PL to include information on the side effect Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome), following approval of the same change for the reference product Pedea. Additionally, the MAH introduced editorial updates: (1) aligning Section 4.9 of the SmPC and Section 3 of the PL with the reference product, and (2) correcting a typographical error in Table 1 of Section 4.8 of the NL SmPC.   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000267682 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 27/05/2025 | SmPC                                                                                                                                                                                                                                                                                                                                                                                                                                                  |